Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrilumab in Moderate to Severe Ulcerative Colitis
NCT01694485Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2012
- Primary completion
- Jul 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 2 trial of abrilumab in ulcerative colitis (UC), sponsored by Amgen. Started Nov 2012; status: completed.
02
Drugs
abrilumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01694485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01694485.